Genomic Prediction Welcomes Dr. Santiago Munné as New Chief Scientific Officer
In a significant move to strengthen its leadership in advanced embryo screening, Genomic Prediction, Inc. has announced the appointment of Dr. Santiago Munné, Ph.D., as the new Chief Scientific Officer. Known globally for his pioneering work in reproductive genetics and preimplantation genetic testing, Dr. Munné brings more than 30 years of scientific and clinical expertise to Genomic Prediction. His background positions him perfectly to guide the company's strategic evolution in embryo health assessment.
Dr. Munné obtained his Ph.D. in Human Genetics from the prestigious University of Pittsburgh and is credited with developing several groundbreaking techniques in genetic testing. Notably, he introduced the first Preimplantation Genetic Test for Aneuploidy (PGT-A) in 1993, as well as tests for chromosomal translocations and detecting de novo mutations—critical advancements that have helped redefine practices in in vitro fertilization (IVF). This innovative work has not only reduced miscarriage rates but also improved embryo transfer success rates, further establishing benchmarks in the field of reproductive health.
With over 270 peer-reviewed scientific publications to his name, Dr. Munné has been recognized numerous times for his contributions to reproductive genetics. From 2011 to 2022, he was honored with the ASRM Star Awards for twelve consecutive years, highlighting his impact on the field. In 2024, his team received the Robert G. Edwards Prize Paper Award, affirming the clinical significance of their work involving automated intracytoplasmic sperm injection (ICSI).
Dr. Munné's influence extends beyond the laboratory; he has played an instrumental role in transforming scientific innovations into practical clinical applications. He co-founded Reprogenetics, the first commercial PGT laboratory, which successfully performed over 100,000 procedures before being acquired by Cooper Companies. This venture demonstrated his proficiency in translating research breakthroughs into real-world solutions for patients facing infertility challenges.
Later, he established Recombine, a genetic carrier screening company, which was also acquired by Cooper Companies. His trajectory continued with the launch of Overture Life, a company dedicated to automating IVF laboratory processes, which has contributed to the publication of the first babies conceived using automated ICSI in 2023. Dr. Munné has also founded HoMu Health Ventures, which is focused on supporting early-stage biomedical research targeting women's and reproductive health issues.
Kelly Ketterson, CEO of Genomic Prediction, expressed enthusiasm for Dr. Munné’s appointment, stating, "Santiago Munné is one of the most influential scientists in reproductive genetics, and his work has shaped how the field understands embryo viability and genetic risk. His depth of expertise, scientific rigor, and proven ability to move breakthrough science into clinical reality make him uniquely suited to lead Genomic Prediction's scientific vision. We are honored to welcome him as Chief Scientific Officer."
In this pivotal role, Dr. Munné will spearhead Genomic Prediction’s scientific strategy, oversee research and innovation initiatives, and manage the growth of the company’s proprietary LifeView® platform and the Embryo Health Score™ (EHS). This platform is designed to leverage genomic insights to improve IVF outcomes and deepen understanding of long-term health factors.
Genomic Prediction, Inc. is at the forefront of advanced embryo screening, utilizing their cutting-edge LifeView® technology to assess the genetic health of embryos. The LifeView Embryo Health Score™ (EHS) evaluates the potential for developing conditions influenced by multiple genetic factors, such as cardiovascular diseases, diabetes, certain cancers, and mental health disorders. EHS results are derived from the same embryo samples engaged in PGT testing processes, thus reinforcing the interconnectedness of their methodologies.
In conclusion, Dr. Santiago Munné’s wealth of expertise and commitment to innovation in reproductive genetics will undeniably propel Genomic Prediction toward its objectives. His leadership is expected to enhance the company's mission to optimize embryo health and IVF success rates, ultimately benefiting countless families aspiring to conceive.
Dr. Munné obtained his Ph.D. in Human Genetics from the prestigious University of Pittsburgh and is credited with developing several groundbreaking techniques in genetic testing. Notably, he introduced the first Preimplantation Genetic Test for Aneuploidy (PGT-A) in 1993, as well as tests for chromosomal translocations and detecting de novo mutations—critical advancements that have helped redefine practices in in vitro fertilization (IVF). This innovative work has not only reduced miscarriage rates but also improved embryo transfer success rates, further establishing benchmarks in the field of reproductive health.
With over 270 peer-reviewed scientific publications to his name, Dr. Munné has been recognized numerous times for his contributions to reproductive genetics. From 2011 to 2022, he was honored with the ASRM Star Awards for twelve consecutive years, highlighting his impact on the field. In 2024, his team received the Robert G. Edwards Prize Paper Award, affirming the clinical significance of their work involving automated intracytoplasmic sperm injection (ICSI).
Dr. Munné's influence extends beyond the laboratory; he has played an instrumental role in transforming scientific innovations into practical clinical applications. He co-founded Reprogenetics, the first commercial PGT laboratory, which successfully performed over 100,000 procedures before being acquired by Cooper Companies. This venture demonstrated his proficiency in translating research breakthroughs into real-world solutions for patients facing infertility challenges.
Later, he established Recombine, a genetic carrier screening company, which was also acquired by Cooper Companies. His trajectory continued with the launch of Overture Life, a company dedicated to automating IVF laboratory processes, which has contributed to the publication of the first babies conceived using automated ICSI in 2023. Dr. Munné has also founded HoMu Health Ventures, which is focused on supporting early-stage biomedical research targeting women's and reproductive health issues.
Kelly Ketterson, CEO of Genomic Prediction, expressed enthusiasm for Dr. Munné’s appointment, stating, "Santiago Munné is one of the most influential scientists in reproductive genetics, and his work has shaped how the field understands embryo viability and genetic risk. His depth of expertise, scientific rigor, and proven ability to move breakthrough science into clinical reality make him uniquely suited to lead Genomic Prediction's scientific vision. We are honored to welcome him as Chief Scientific Officer."
In this pivotal role, Dr. Munné will spearhead Genomic Prediction’s scientific strategy, oversee research and innovation initiatives, and manage the growth of the company’s proprietary LifeView® platform and the Embryo Health Score™ (EHS). This platform is designed to leverage genomic insights to improve IVF outcomes and deepen understanding of long-term health factors.
Genomic Prediction, Inc. is at the forefront of advanced embryo screening, utilizing their cutting-edge LifeView® technology to assess the genetic health of embryos. The LifeView Embryo Health Score™ (EHS) evaluates the potential for developing conditions influenced by multiple genetic factors, such as cardiovascular diseases, diabetes, certain cancers, and mental health disorders. EHS results are derived from the same embryo samples engaged in PGT testing processes, thus reinforcing the interconnectedness of their methodologies.
In conclusion, Dr. Santiago Munné’s wealth of expertise and commitment to innovation in reproductive genetics will undeniably propel Genomic Prediction toward its objectives. His leadership is expected to enhance the company's mission to optimize embryo health and IVF success rates, ultimately benefiting countless families aspiring to conceive.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.